Recently, both ACE2 and B0AT1 have been targeted pharmacologically, with the compounds DX600 and benztropine respectively, to reduce SARS-CoV-2 spike dependent viral infection in a human embryonic stem cell derived cardiomyocyte model23. The gene discussed is ACE2; the disease is viral infectious disease.